GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Daptomycin

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug6 sources available - open source summaries, references and comparisons

Cubicin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Do not merge label and higher-dose institutional dialysis protocols

The label includes CrCl exactly 30 in its >=30 band. UCSF prints >30 and <30, omitting exactly 30, and uses higher doses and different HD scheduling.

Before applying: Keep source-specific dose, interval, indication, weight basis and modality together. The official threshold is explicit; seek institutional clarification rather than silently changing its headings.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (6)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Daptomycin for injection - Fresenius Kabi USA 500 mg vial

Product / population
Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.
Renal measure
CrCl in mL/min; Cockcroft-Gault with actual body weight in the selected PK table
Before using this finding

The source explicitly includes exactly CrCl 30; do not silently repair a different institutional heading.

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Renal dosing, restrictions and evidence limits

The Fresenius Kabi label places CrCl exactly 30 mL/min in the at-least-30 category. Adult cSSSI uses 4 mg/kg every 24 hours and S. aureus bloodstream infection 6 mg/kg every 24 hours. Below 30, including HD/CAPD, the respective doses are every 48 hours, after HD when possible. Renal function and CPK require monitoring more often than once weekly in renal impairment. Pediatric renal regimens are unestablished. Reconstitution and storage differ among daptomycin formulations; this source does not establish interchangeability of preparation instructions.

Source revision: 5/2022 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa514937-e025-4ea7-b62a-385eb056ae70

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Daptomycin for injection - Fresenius Kabi USA 500 mg vial

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

GlobalRPh RX List - CUBICIN RF

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

UCSF daptomycin - adult dosing guidance

Authored v6.0; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

A regimen is reported in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Official product label

Daptomycin for injection - Fresenius Kabi USA 500 mg vial

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

The source explicitly includes exactly CrCl 30; do not silently repair a different institutional heading.

Dialysis evidence: A regimen is reported in selected content

Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.

Renal method: CrCl in mL/min; Cockcroft-Gault with actual body weight in the selected PK table
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - CUBICIN RF

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Keep the infection-specific dose, interval and dialysis schedule from the same source.

Dialysis evidence: A regimen is reported in selected content

Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.

Renal method: CrCl in mL/min; selected PK table specifies Cockcroft-Gault using actual body weight
Retrieved: 2026-09-10

Read local renal resultOpen original reference
Professional guidance

UCSF - daptomycin: high-dose institutional regimen

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF daptomycin - adult dosing guidance

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Before using this finding

Higher-dose institutional regimens and the missing exactly-30 heading require source-specific review, not dose/interval mixing.

Dialysis evidence: A regimen is reported in selected content

Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.

Renal method: Institutional CrCl headings; source-specific weight selection and CVVHD flow caveats
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Do not merge label and higher-dose institutional dialysis protocols

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

renal boundary and dialysis protocol difference

Do not merge label and higher-dose institutional dialysis protocols

The label includes CrCl exactly 30 in its >=30 band. UCSF prints >30 and <30, omitting exactly 30, and uses higher doses and different HD scheduling.

How to use this: Keep source-specific dose, interval, indication, weight basis and modality together. The official threshold is explicit; seek institutional clarification rather than silently changing its headings.

GlobalRPh RX List - CUBICIN RFDaptomycin for injection - Fresenius Kabi USA 500 mg vialUCSF daptomycin - adult dosing guidance

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeDaptomycin for injection - Fresenius Kabi USA 500 mg vialGlobalRPh RX List - CUBICIN RFNebraska Medicine daptomycinUCSF - daptomycin: high-dose institutional regimenUCSF daptomycin - adult dosing guidance
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/daptomycin/

Usual Dosing (Adults)

Complicated skin/skin structure infection: CUBICIN 4 mg/kg IV over 30 minutes in 0.9% sodium chloride every 24 hours for 7 to 14 days.

S. aureus bloodstream infection, including right-sided endocarditis due to MSSA or MRSA: 6 mg/kg IV over 30 minutes in 0.9% sodium chloride every 24 hours for a minimum of 2 to 6 weeks, with duration based on the working diagnosis. The source notes limited safety data beyond 28 days; in its cited phase 3 study, 14 patients received >28 days and 8 received >=6 weeks.

CPK elevation appeared more common with more-than-once-daily dosing in phase 1/2 trials, so do not dose more frequently than once daily.

GRPH-daptomycin-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Primarily eliminated by the kidneys. In renal impairment, check renal function and CPK more often than weekly. The source clearance method is Cockcroft-Gault using actual body weight.

CrClSkin/skin structureS. aureus bloodstream infection
>=30 mL/min4 mg/kg every 24 hours6 mg/kg every 24 hours
<30 mL/min, including HD or CAPD4 mg/kg every 48 hours6 mg/kg every 48 hours
GRPH-daptomycin-02 · Source section: Renal DosingRenal section finder

Hemodialysis

When possible, administer after completion of hemodialysis on dialysis days.

GRPH-daptomycin-03 · Source section: HemodialysisRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Daptomycin for injection - Fresenius Kabi USA 500 mg vial

Open original reference

Open / share this exact local source

DailyMed / Fresenius Kabi USA, LLC · Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.

Renal method: CrCl in mL/min; Cockcroft-Gault with actual body weight in the selected PK table
Source date: 5/2022
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

The source explicitly includes exactly CrCl 30; do not silently repair a different institutional heading.

Dialysis evidence: A regimen is reported in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The Fresenius Kabi label places CrCl exactly 30 mL/min in the at-least-30 category. Adult cSSSI uses 4 mg/kg every 24 hours and S. aureus bloodstream infection 6 mg/kg every 24 hours. Below 30, including HD/CAPD, the respective doses are every 48 hours, after HD when possible. Renal function and CPK require monitoring more often than once weekly in renal impairment. Pediatric renal regimens are unestablished. Reconstitution and storage differ among daptomycin formulations; this source does not establish interchangeability of preparation instructions.

RDM60-official-daptomycin-a985bbc40d-C1 · Source locator: 2.6 Table 3; 2.7; 8.6; 12.3 Table 12 footnote

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Selected exact-product labeling sections read. Original-source bytes and complete revision histories were not retained or reconciled; retrieval does not establish current product availability.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa514937-e025-4ea7-b62a-385eb056ae70
Retrieved
2026-09-10
Exact label title
Daptomycin for injection - Fresenius Kabi USA 500 mg vial
DailyMed Set ID
fa514937-e025-4ea7-b62a-385eb056ae70
Labeler
Fresenius Kabi USA, LLC
Label revision
5/2022
Archive publication date
2023-01-09
SPL version
5
FDA application
ANDA206077
Renal-function method
CrCl in mL/min; Cockcroft-Gault with actual body weight in the selected PK table
Source date/version
5/2022
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
4761efeeb9743e10ab79e7fb5ccbfe5a581155be313384c59dad79b2a9583919
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - CUBICIN RF

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.

Renal method: CrCl in mL/min; selected PK table specifies Cockcroft-Gault using actual body weight
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Keep the infection-specific dose, interval and dialysis schedule from the same source.

Dialysis evidence: A regimen is reported in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The CUBICIN RF mirror gives 4 mg/kg every 24 hours for adult complicated skin/skin-structure infection and 6 mg/kg every 24 hours for adult S. aureus bloodstream infection when CrCl is at least 30 mL/min. Below 30, including HD and CAPD, the respective doses are given every 48 hours; administer after HD when possible. Pediatric renal dosing is not established. In renal impairment, renal function and CPK need assessment more frequently than weekly. These indication-specific label regimens are not the UCSF higher-dose protocol.

RDM60-rxlist-daptomycin-67b6cac58a-C1 · Source locator: Dosage: renal impairment; warnings/renal monitoring; PK renal-table footnote

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. See the separately attributed official source; concordance is limited to selected sections.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/cubicin-rf-drug/
Retrieved
2026-09-10
Renal-function method
CrCl in mL/min; selected PK table specifies Cockcroft-Gault using actual body weight
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
4bc53b24740070925dc202167c80280bc17cdc5c462c8ad3f87ac582429e83e4
Separate professional-source layer

University and professional protocols

Professional

Nebraska Medicine daptomycin

Open original reference

Open / share this exact local source

UNMC / Nebraska Medicine · Adult IV; exact displayed source row reviewed visually.

Renal method: Not specified in this summary.
Source date: Not independently captured
Retrieved: 2026-09-05

Source recheck unresolved. Prior follow-up retrieval/version warning retained; not resolved by v6.0. Read source-review status

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Adult regimen and renal adjustment

The displayed table uses 6 mg/kg IV daily for bacteremia, osteomyelitis and other severe infections, or 4 mg/kg daily for UTI/skin infection. At CrCl <30 mL/min it retains the selected dose but extends the interval to every 48 hours. HD follows the <30 interval, with administration after dialysis on treatment days.

daptomycin:unmc-daptomycin-1 · Source locator: Rendered PDF page 21: daptomycin row

Source-specific limits

This institutional source includes off-label indications. Its outpatient post-HD and higher-dose salvage options were not imported here. Parsed-text page numbers did not match the rendered PDF; this summary uses the displayed page, not the conflicting parsed locations.

Source identity and provenance
Source
https://www.unmc.edu/intmed/_documents/id/asp/dose-nm-anti-infective-renal-dosing-guidelines.pdf
Retrieved
2026-09-05
Source date/version
Not independently captured
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
2a46f7b947eba7f903f11ef28837c73a2e59dc6c43cd3edaff3fb65c179c700c
Professional

UCSF - daptomycin: high-dose institutional regimen

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

IV dosing at CrCl >30 mL/min is 8-10 mg/kg daily; below 30, 8-10 mg/kg every 48 hours. The webpage omits exactly 30. Certain VRE infections may require up to 12 mg/kg with ID pharmacy guidance.

IHD: 8-10 mg/kg initially and after HD; an unstable dialysis schedule may instead use every-48-hour dosing. CVVHD: 6-8 mg/kg daily. Flow above 2.5 L/hour can require higher dosing; obtain specialist input. This continuous regimen has not been evaluated for other modalities such as CVVH.

Weight is total body weight unless it exceeds 120% of ideal body weight, when UCSF uses adjusted weight. Daptomycin is not effective for pneumonia. These high-dose institutional recommendations remain distinct from label regimens.

RDM30-017-daptomycin-1 · Source locator: UCSF - daptomycin: high-dose institutional regimen; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/daptomycin
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
3498e24eea55d29cd8ac79fc1a98e3285f46b4718a55d31db74ea2fbcf1c96a8
Professional

UCSF daptomycin - adult dosing guidance

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adult intravenous daptomycin. Product preparation, infection indication and institution-specific higher-dose regimens must remain separately attributed.

Renal method: Institutional CrCl headings; source-specific weight selection and CVVHD flow caveats
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.
Before using this finding

Higher-dose institutional regimens and the missing exactly-30 heading require source-specific review, not dose/interval mixing.

Dialysis evidence: A regimen is reported in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

UCSF prints CrCl >30 and <30 headings with 8-10 mg/kg IV every 24 and 48 hours, respectively; exactly 30 is absent from those headings. Its intermittent-HD schedule is 8-10 mg/kg once now and after HD, with every-48-hour dosing as an alternative when the HD schedule is unstable. CVVHD uses 6-8 mg/kg every 24 hours; flow above 2.5 L/hour may require more with ID/ASP input. Other continuous modalities, including CVVH, were not evaluated. UCSF uses total weight unless above 120% of ideal weight, then adjusted weight. Therapy is restricted and is not for pneumonia.

RDM60-professional-daptomycin-7bdcd6bd4c-C1 · Source locator: Dosing weights; adult non-dialysis; HD/CVVHD; restrictions

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

Institutional guidance, not a universal protocol; local specialist and patient-context review remain necessary.

Source identity and provenance
Source family
professional_guidance
Source
https://idmp.ucsf.edu/content/daptomycin
Retrieved
2026-09-10
Renal-function method
Institutional CrCl headings; source-specific weight selection and CVVHD flow caveats
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
55929cd9bb93d43475443b9b9579167433a97c97739340b411ec1600c9d1a163

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 3 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/daptomycin/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
e5d797493e69a5c956d76f53c22648ef7238af3f1d18b192a960035b28682c7c
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report